Article info

Download PDFPDF

Rationale for the ASSAIL-MI-trial: a randomised controlled trial designed to assess the effect of tocilizumab on myocardial salvage in patients with acute ST-elevation myocardial infarction (STEMI)

Authors

  • Anne Kristine Anstensrud Department of Cardiology, Oslo University Hospital Rikshospitalet, Oslo, NorwayFaculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway PubMed articlesGoogle scholar articles
  • Sindre Woxholt Clinic of Cardiology, St. Olavs Hospital, Trondheim University Hospital, Trondheim, NorwayDepartment of Circulation and Medical Imaging, Norwegian University of Science and Technology (NTNU), Trondheim, Norway PubMed articlesGoogle scholar articles
  • Kapil Sharma Department of Cardiology, Oslo University Hospital Ullevaal, Oslo, Norway PubMed articlesGoogle scholar articles
  • Kaspar Broch Department of Cardiology, Oslo University Hospital Rikshospitalet, Oslo, NorwayK.G. Jebsen Cardiac Research Centre and Centre for Heart Failure Research, University of Oslo, Oslo, Norway PubMed articlesGoogle scholar articles
  • Bjørn Bendz Department of Cardiology, Oslo University Hospital Rikshospitalet, Oslo, NorwayFaculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway PubMed articlesGoogle scholar articles
  • Svend Aakhus Department of Circulation and Medical Imaging, Norwegian University of Science and Technology (NTNU), Trondheim, Norway PubMed articlesGoogle scholar articles
  • Thor Ueland Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, NorwayK.G.Jebsen Thrombosis Research and Expertise Center (TREC), The Arctic University of Norway, Tromsø, Norway PubMed articlesGoogle scholar articles
  • Brage H Amundsen Clinic of Cardiology, St. Olavs Hospital, Trondheim University Hospital, Trondheim, NorwayDepartment of Circulation and Medical Imaging, Norwegian University of Science and Technology (NTNU), Trondheim, Norway PubMed articlesGoogle scholar articles
  • Jan Kristian Damås Department of Infectious Disease, St. Olavs Hospital, Trondheim University Hospital, Oslo, NorwayDepartment of Clinical and Molecular Medicine, Centre of Molecular Inflammation Research, Norwegian University of Science and Technology (NTNU), Trondheim, Norway PubMed articlesGoogle scholar articles
  • Einar Hopp Division of Radiology and Nuclear Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway PubMed articlesGoogle scholar articles
  • Ola Kleveland Clinic of Cardiology, St. Olavs Hospital, Trondheim University Hospital, Trondheim, NorwayDepartment of Circulation and Medical Imaging, Norwegian University of Science and Technology (NTNU), Trondheim, Norway PubMed articlesGoogle scholar articles
  • Knut Haakon Stensæth Department of Circulation and Medical Imaging, Norwegian University of Science and Technology (NTNU), Trondheim, NorwayDepartment of Radiology and Nuclear Medicine, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway PubMed articlesGoogle scholar articles
  • Anders Opdahl Department of Cardiology, Oslo University Hospital Rikshospitalet, Oslo, Norway PubMed articlesGoogle scholar articles
  • Nils-Einar Kløw Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, NorwayDepartment of Radiology, Oslo University Hospital Ullevaal, Oslo, Norway PubMed articlesGoogle scholar articles
  • Ingebjørg Seljeflot Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, NorwayDepartment of Cardiology, Center for Clinical Heart Research, Oslo University Hospital Ullevaal, Oslo, Norway PubMed articlesGoogle scholar articles
  • Geir Øystein Andersen Department of Cardiology, Oslo University Hospital Ullevaal, Oslo, NorwayDepartment of Cardiology, Center for Clinical Heart Research, Oslo University Hospital Ullevaal, Oslo, Norway PubMed articlesGoogle scholar articles
  • Rune Wiseth Clinic of Cardiology, St. Olavs Hospital, Trondheim University Hospital, Trondheim, NorwayDepartment of Circulation and Medical Imaging, Norwegian University of Science and Technology (NTNU), Trondheim, Norway PubMed articlesGoogle scholar articles
  • Pål Aukrust Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, NorwayDepartment of Rheumatology, Dermatology and Infectious Disease, Oslo University Hospital Rikshospitalet, Oslo, Norway PubMed articlesGoogle scholar articles
  • Lars Gullestad Department of Cardiology, Oslo University Hospital Rikshospitalet, Oslo, NorwayFaculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway PubMed articlesGoogle scholar articles
  1. Correspondence to Anne Kristine Anstensrud; annans{at}ous-hf.no
View Full Text

Citation

Anstensrud AK, Woxholt S, Sharma K, et al
Rationale for the ASSAIL-MI-trial: a randomised controlled trial designed to assess the effect of tocilizumab on myocardial salvage in patients with acute ST-elevation myocardial infarction (STEMI)

Publication history

  • Received June 9, 2019
  • Accepted September 12, 2019
  • First published October 15, 2019.
Online issue publication 
October 15, 2019

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.